Phase 2 × Terminated × Myelodysplastic Syndromes × Clear all Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Phase 2 Terminated
235 enrolled
ACHIEVE
Phase 2 Terminated
16 enrolled
5
Phase 2 Terminated
10 enrolled
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Phase 2 Terminated
53 enrolled
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Phase 2 Terminated
7 enrolled 12 charts
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Phase 2 Terminated
5 enrolled
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Phase 2 Terminated
43 enrolled 14 charts
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Phase 2 Terminated
21 enrolled
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
46 enrolled 18 charts
GVAX vs. Placebo for MDS/AML After Allo HSCT
Phase 2 Terminated
123 enrolled 26 charts
T-cell Depleted Alternative Donor Transplantation
Phase 2 Terminated
53 enrolled 14 charts
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Phase 2 Terminated
3 enrolled 4 charts
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
Phase 2 Terminated
9 enrolled 8 charts
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
Phase 2 Terminated
13 enrolled 5 charts
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
Phase 2 Terminated
6 enrolled 8 charts
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase 2 Terminated
342 enrolled 14 charts
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Phase 2 Terminated
10 enrolled 8 charts
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Phase 2 Terminated
32 enrolled
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase 2 Terminated
442 enrolled 17 charts
SAMBA
Phase 2 Terminated
25 enrolled
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
Phase 2 Terminated
3 enrolled 6 charts
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
3 enrolled 6 charts
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 2 Terminated
17 enrolled 5 charts
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
5 enrolled
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Phase 2 Terminated
2 enrolled 5 charts
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase 2 Terminated
1 enrolled
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Phase 2 Terminated
14 enrolled
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Phase 2 Terminated
5 enrolled
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Phase 2 Terminated
33 enrolled 11 charts
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Phase 2 Terminated
16 enrolled 19 charts
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Phase 2 Terminated
24 enrolled 15 charts
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Phase 2 Terminated
4 enrolled 5 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Terminated
16 enrolled 7 charts
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Phase 2 Terminated
4 enrolled 11 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Phase 2 Terminated
7 enrolled 8 charts